$6.95
1.46% yesterday
Nasdaq, Sep 03, 10:14 pm CET
ISIN
US00289Y1073
Symbol
ABEO

Abeona Therapeutics, Inc. Target price 2025 - Analyst rating & recommendation

Abeona Therapeutics, Inc. Classifications & Recommendation:

Buy
92%
Hold
8%

Abeona Therapeutics, Inc. Price Target

Target Price $20.40
Price $6.95
Potential
Number of Estimates 9
9 Analysts have issued a price target Abeona Therapeutics, Inc. 2026 . The average Abeona Therapeutics, Inc. target price is $20.40. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 12 analysts: 11 Analysts recommend Abeona Therapeutics, Inc. to buy, 1 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Abeona Therapeutics, Inc. stock has an average upside potential 2026 of . Most analysts recommend the Abeona Therapeutics, Inc. stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Million $ 0.00 27.07
100.00%

9 Analysts have issued a sales forecast Abeona Therapeutics, Inc. 2025 . The average Abeona Therapeutics, Inc. sales estimate is

$27.1m
Unlock
. This is
6,668.25% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$33.6m 8,289.50%
Unlock
, the lowest is
$16.1m 3,918.00%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $0.0 100.00%
2026
$119m 339.63%
Unlock
2027
$206m 73.43%
Unlock
2028
$310m 50.10%
Unlock
2029
$388m 25.27%
Unlock
2030
$446m 15.01%
Unlock
2031
$487m 9.09%
Unlock
2032
$497m 2.06%
Unlock

9 Abeona Therapeutics, Inc. Analysts have issued a net profit forecast 2025. The average Abeona Therapeutics, Inc. net profit estimate is

$-5.0m
Unlock
. This is
108.77% lower
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$53.8m 5.99%
Unlock
, the lowest is
$-51.7m 190.37%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $-63.7m 17.60%
2025
$-5.0m 92.12%
Unlock
2026
$5.9m 217.53%
Unlock
2027
$59.2m 903.05%
Unlock
2028
$105m 77.54%
Unlock
2029
$123m 17.17%
Unlock
2030
$146m 18.26%
Unlock
2031
$163m 11.67%
Unlock
2032
$171m 5.46%
Unlock

Net Margin

2026
4.96% 126.75%
Unlock
2027
28.67% 478.02%
Unlock
2028
33.91% 18.28%
Unlock
2029
31.72% 6.46%
Unlock
2030
32.61% 2.81%
Unlock
2031
33.39% 2.39%
Unlock
2032
34.50% 3.32%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ -1.55 -0.10
38.74% 93.55%
P/E negative
EV/Sales 5.56

9 Analysts have issued a Abeona Therapeutics, Inc. forecast for earnings per share. The average Abeona Therapeutics, Inc. EPS is

$-0.10
Unlock
. This is
111.76% lower
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$1.05 23.53%
Unlock
, the lowest is
$-1.01 218.82%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $-1.55 38.74%
2025
$-0.10 93.55%
Unlock
2026
$0.12 220.00%
Unlock
2027
$1.15 858.33%
Unlock
2028
$2.05 78.26%
Unlock
2029
$2.40 17.07%
Unlock
2030
$2.84 18.33%
Unlock
2031
$3.17 11.62%
Unlock
2032
$3.35 5.68%
Unlock

P/E ratio

Current 8.18 246.32%
2025
-70.98 968.10%
Unlock
2026
60.37 185.05%
Unlock
2027
6.02 90.03%
Unlock
2028
3.39 43.69%
Unlock
2029
2.89 14.75%
Unlock
2030
2.45 15.22%
Unlock
2031
2.19 10.61%
Unlock
2032
2.08 5.02%
Unlock

Based on analysts' sales estimates for 2025, the Abeona Therapeutics, Inc. stock is valued at an EV/Sales of

and an P/S ratio of
13.16
Unlock
.

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 376.06
2025
5.56 98.52%
Unlock
2026
1.26 77.25%
Unlock
2027
0.73 42.34%
Unlock
2028
0.49 33.38%
Unlock
2029
0.39 20.16%
Unlock
2030
0.34 13.05%
Unlock
2031
0.31 8.34%
Unlock
2032
0.30 2.01%
Unlock

P/S ratio

Current
2025
13.16 98.52%
Unlock
2026
2.99 77.25%
Unlock
2027
1.73 42.34%
Unlock
2028
1.15 33.38%
Unlock
2029
0.92 20.17%
Unlock
2030
0.80 13.05%
Unlock
2031
0.73 8.33%
Unlock
2032
0.72 2.02%
Unlock

Current Abeona Therapeutics, Inc. Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
HC Wainwright & Co.
Locked
Locked
Locked Aug 18 2025
Oppenheimer
Locked
Locked
Locked Aug 15 2025
HC Wainwright & Co.
Locked
Locked
Locked Jul 16 2025
HC Wainwright & Co.
Locked
Locked
Locked Jul 14 2025
Stifel
Locked
Locked
Locked May 16 2025
HC Wainwright & Co.
Locked
Locked
Locked Apr 30 2025
HC Wainwright & Co.
Locked
Locked
Locked Mar 24 2025
Analyst Rating Date
Locked
HC Wainwright & Co.:
Locked
Locked
Aug 18 2025
Locked
Oppenheimer:
Locked
Locked
Aug 15 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Jul 16 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Jul 14 2025
Locked
Stifel:
Locked
Locked
May 16 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Apr 30 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Mar 24 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today